Cadence Capital Management LLC lessened its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 35.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 107,511 shares of the company’s stock after selling 58,252 shares during the quarter. Cadence Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $2,615,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Global X Management Co. LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth $123,000. Wealthstreet Investment Advisors LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth $200,000. Greenleaf Trust purchased a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $215,000. Court Place Advisors LLC purchased a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $220,000. Finally, Miracle Mile Advisors LLC purchased a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at about $227,000. 65.50% of the stock is currently owned by institutional investors.

In other Teva Pharmaceutical Industries news, EVP Sven Dethlefs purchased 2,000 shares of the business’s stock in a transaction on Friday, August 3rd. The shares were bought at an average cost of $21.92 per share, for a total transaction of $43,840.00. Following the completion of the purchase, the executive vice president now directly owns 6,445 shares of the company’s stock, valued at $141,274.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Iris Beck Codner sold 4,165 shares of the business’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $22.70, for a total transaction of $94,545.50. Following the sale, the executive vice president now owns 8,290 shares in the company, valued at $188,183. The disclosure for this sale can be found here. 0.43% of the stock is owned by corporate insiders.

Several analysts recently issued reports on TEVA shares. Citigroup boosted their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, June 27th. Goldman Sachs Group boosted their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company a “buy” rating in a report on Monday, June 25th. Credit Suisse Group set a $23.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Monday, May 14th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a report on Monday, July 9th. Finally, Mizuho restated a “buy” rating and issued a $27.00 price objective on shares of Teva Pharmaceutical Industries in a report on Thursday, August 2nd. Nine investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and eight have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $20.45.

Shares of NYSE:TEVA opened at $23.02 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 0.69 and a current ratio of 1.03. The stock has a market cap of $25.59 billion, a price-to-earnings ratio of 5.87, a price-to-earnings-growth ratio of 3.14 and a beta of 0.72. Teva Pharmaceutical Industries Ltd has a 1 year low of $10.85 and a 1 year high of $25.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.64 by $0.14. The company had revenue of $4.70 billion for the quarter, compared to analyst estimates of $4.75 billion. Teva Pharmaceutical Industries had a negative net margin of 47.98% and a positive return on equity of 19.92%. The business’s revenue for the quarter was down 17.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.02 earnings per share. analysts anticipate that Teva Pharmaceutical Industries Ltd will post 2.67 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Featured Article: Price to Earnings Ratio (PE), For Valuing Stocks

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.